search
Back to results

Evaluation of Treatment Option for Demodicosis in Patients Undergoing Cataract Surgery

Primary Purpose

Demodex Infestation, Demodicosis, Cataract

Status
Completed
Phase
Phase 2
Locations
Mexico
Study Type
Interventional
Intervention
Tea Tree Oil Shampoo
Ciprofloxacin Ophthalmic Ointment 0.3%
Baby shampoo
Blephaclean
Sponsored by
Hospital de La Luz
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Demodex Infestation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed informed consent after explanation of the nature and possible consequences of the study.
  • Clinical diagnosis of cataracts staged with Lens Opacity Classification System III based on the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery guidelines.
  • No topical antibiotic ointment therapy or eyelid cleansing in the past six months.
  • No systemic antibiotic or antiparasite treatment in the past six months.
  • No ocular comorbidities (other than cataracts)
  • No systemic comorbidities.

Exclusion Criteria:

  • Withdrawal from the study.
  • Minimal changes based on the Lens Opacity Classification System III.

Sites / Locations

  • Hospital de la Luz

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Other

Active Comparator

Active Comparator

Experimental

Arm Label

Group 1: Topical 0.3% Ciprofloxacin [Cipro]

Group 2: Cipro + 50% diluted baby shampoo

Group 3: Cipro + Blephaclean

Group 4: Cipro + Tea tree oil.

Arm Description

Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days.

Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with 50% diluted baby shampoo for three days.

Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with Blephaclean Sterile Eyelid Wipes (Thea Pharmaceuticals) for three days.

Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with tea tree oil shampoo for three days.

Outcomes

Primary Outcome Measures

Mean Demodex spp. infestation index by intervention group
Number of demodex (egg, larvae, nymph, adult-form) spp. per eyelash (taken from epilation).
Crude count of Demodex spp. adult-forms (mites) in eyelashes by intervention group
Number of demodex (egg, larvae, nymph, adult-form) spp. in total (taken from epilation).

Secondary Outcome Measures

Endophthalmitis in the postoperative period.
Number of cases diagnosed with endophthalmitis in the postoperative period.

Full Information

First Posted
December 14, 2019
Last Updated
April 23, 2020
Sponsor
Hospital de La Luz
Collaborators
Claudia Palacio Pastrana, M.D., M.Sc., Samuel J. Avalos Lara, M.D., Hector Perez Cano, Ph.D., Bani Antonio-Aguirre, M.D., M.P.H.c., Cristina Mendoza-Velasquez, M.D., M.Sc., Azyadeh Camacho-Ordóñez, M.D., M.Sc.c., Andric C. Perez-Ortiz, M.D., M.P.H.
search

1. Study Identification

Unique Protocol Identification Number
NCT04204954
Brief Title
Evaluation of Treatment Option for Demodicosis in Patients Undergoing Cataract Surgery
Official Title
A Randomized Controlled Trial of Treatment Efficacy in Ameliorating Demodex Spp. Infestation Among Cases Undergoing Cataract Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
April 2020
Overall Recruitment Status
Completed
Study Start Date
May 6, 2019 (Actual)
Primary Completion Date
November 14, 2019 (Actual)
Study Completion Date
December 13, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital de La Luz
Collaborators
Claudia Palacio Pastrana, M.D., M.Sc., Samuel J. Avalos Lara, M.D., Hector Perez Cano, Ph.D., Bani Antonio-Aguirre, M.D., M.P.H.c., Cristina Mendoza-Velasquez, M.D., M.Sc., Azyadeh Camacho-Ordóñez, M.D., M.Sc.c., Andric C. Perez-Ortiz, M.D., M.P.H.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Demodex blepharitis is a prevalent cause of comorbid infection among individuals undergoing cataract surgery. Several complications may arise in the postsurgical period from Staphylococcus or Streptococcus co-infections, as Demodex is a vector for these pathogens. Hence, prophylactic treatments before cataract surgery may lead to a reduction in complication rates. Since Demodex infestation and cataract surgery are two prevalent coexisting conditions in the general population, this study aims to test the effect of four combined treatments to eradicate or improve the Demodex infestation index before surgery. The investigators are conducting a single-blinded randomized trial of four therapies in participants undergoing cataract surgery. All participants will or are receiving daily eyelid cleansing bid and topical 0.3% ciprofloxacin q4h for three days added to the allocated treatment arm. Our four intervention groups are: [1] Blephaclean eye scrubs; [2] 50% dilution baby shampoo; [3] tea tree oil shampoo; [4]: topical 0.3% ciprofloxacin alone. To assess treatment efficacy, the investigators will perform eyelash hair epilation pre and postoperatively. The primary outcome is a change in the mean Demodex spp. infestation index. Also, a change in the crude number of Demodex (egg, larvae, nymph, or adult-form) spp. in eyelashes after one-week of therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Demodex Infestation, Demodicosis, Cataract

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Patients diagnosed with Demodex spp. infestation undergoing cataract surgery were randomly allocated into four comparison groups a control group (standard treatment) and three new modalities of Demodex therapy (Blephaclean, baby shampoo, and tea tree oil) + conventional treatment.
Masking
InvestigatorOutcomes Assessor
Masking Description
Investigators and outcomes assessors were blinded to the treatment allocation of each participant. Outcome assessors were anterior segment surgeons who evaluated cases prior to cataract surgery. There was no indication of group allocation in the electronic medical records (EMR), only the participation of each candidate in the study. Similarly, investigators were blinded to group allocation and only recorded data directly from EMR. Blinding was kept after data analysis.
Allocation
Randomized
Enrollment
160 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1: Topical 0.3% Ciprofloxacin [Cipro]
Arm Type
Other
Arm Description
Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days.
Arm Title
Group 2: Cipro + 50% diluted baby shampoo
Arm Type
Active Comparator
Arm Description
Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with 50% diluted baby shampoo for three days.
Arm Title
Group 3: Cipro + Blephaclean
Arm Type
Active Comparator
Arm Description
Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with Blephaclean Sterile Eyelid Wipes (Thea Pharmaceuticals) for three days.
Arm Title
Group 4: Cipro + Tea tree oil.
Arm Type
Experimental
Arm Description
Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with tea tree oil shampoo for three days.
Intervention Type
Other
Intervention Name(s)
Tea Tree Oil Shampoo
Intervention Description
Twice a day eyelid margin cleansing for three days.
Intervention Type
Drug
Intervention Name(s)
Ciprofloxacin Ophthalmic Ointment 0.3%
Intervention Description
Applied topically in the eyelid margin every four hours for three days.
Intervention Type
Other
Intervention Name(s)
Baby shampoo
Other Intervention Name(s)
50% diluted baby shampoo
Intervention Description
Twice a day eyelid margin cleansing for three days.
Intervention Type
Other
Intervention Name(s)
Blephaclean
Intervention Description
Twice a day eyelid margin cleansing for three days.
Primary Outcome Measure Information:
Title
Mean Demodex spp. infestation index by intervention group
Description
Number of demodex (egg, larvae, nymph, adult-form) spp. per eyelash (taken from epilation).
Time Frame
One week.
Title
Crude count of Demodex spp. adult-forms (mites) in eyelashes by intervention group
Description
Number of demodex (egg, larvae, nymph, adult-form) spp. in total (taken from epilation).
Time Frame
One week.
Secondary Outcome Measure Information:
Title
Endophthalmitis in the postoperative period.
Description
Number of cases diagnosed with endophthalmitis in the postoperative period.
Time Frame
One week.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed informed consent after explanation of the nature and possible consequences of the study. Clinical diagnosis of cataracts staged with Lens Opacity Classification System III based on the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery guidelines. No topical antibiotic ointment therapy or eyelid cleansing in the past six months. No systemic antibiotic or antiparasite treatment in the past six months. No ocular comorbidities (other than cataracts) No systemic comorbidities. Exclusion Criteria: Withdrawal from the study. Minimal changes based on the Lens Opacity Classification System III.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Claudia Palacio Pastrana, M.D., M.P.H.
Organizational Affiliation
Hospital de La Luz
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital de la Luz
City
Mexico City
ZIP/Postal Code
06030
Country
Mexico

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of Treatment Option for Demodicosis in Patients Undergoing Cataract Surgery

We'll reach out to this number within 24 hrs